InvestorsHub Logo
Followers 829
Posts 119609
Boards Moderated 14
Alias Born 09/05/2002

Re: DewDiligence post# 1761

Tuesday, 08/06/2019 4:07:21 PM

Tuesday, August 06, 2019 4:07:21 PM

Post# of 2958
ENTA FY3Q19 results:

https://www.enanta.com/investors/news-releases/press-release/2019/Enanta-Pharmaceuticals-Reports-Financial-Results-for-its-Fiscal-Third-Quarter-Ended-June-30-2019/default.aspx

FY3Q19 royalty revenue=$44.4M, up from $39.6M in FY2Q19 (Jan-Mar 2019).

ENTA’s royalty rate from ABBV resets to the lowest tier at the start of each calendar year; the royalty tiers applicable to the 50% Glecaprevir component of Mavyret are shown in #msg-142808661.

ENTA’s 6/30/19 cash balance=$389.2M.

FY3Q19 GAAP EPS=$0.33 (including an $0.04 tax credit).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ENTA News